anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Diabetic stress acts on the cardiac tissue to induce cardiac hypertrophy and fibrosis. Diabetes induced activated renin angiotensin system (RAS) has been reported to play a critical role in mediating cardiac hypertrophy and fibrosis. Angiotensin converting enzyme (ACE) in producing Angiotensin-II, promotes cardiomyocyte hypertrophy and fibrotic damage. ACE2, a recently discovered molecule structurally homologous to ACE, has been reported to be beneficial in reducing the effect of RAS driven pathologies.
METHODS: In vivo diabetic mouse model was used and co-labelling immunostaining assay have been performed to analyse the fibrotic remodeling and involvement of associated target signaling molecules in mouse heart tissue. For in vitro analyses, qPCR and western blot experiments were performed in different groups for RNA and protein expression analyses.
RESULTS: Fibrosis markers were observed to be upregulated in the diabetic mouse heart tissue as well as in high glucose treated fibroblast and cardiomyocyte cells. Hyperglycemia induced overexpression of YAP1 leads to increased expression of β-catenin (CTNNB1) and ACE with downregulated ACE2 expression. The differential expression of ACE/ACE2 promotes TGFB1-SMAD2/3 pathway in the hyperglycemic cardiomyocyte and fibroblast resulting in increased cardiac fibrotic remodeling.
CONCLUSION: In the following study, we have reported YAP1 modulates the RAS signaling pathway by inducing ACE and inhibiting ACE2 activity to augment cardiomyocyte hypertrophy and fibrosis in hyperglycemic condition. Furthermore, we have shown that hyperglycemia induced dysregulation of ACE-ACE2 activity by YAP1 promotes cardiac fibrosis through β-catenin/TGFB1 dependent pathway.
PURPOSE: A composition containing Cannabis sativa extract for preventing or treating dental caries is provided to ensure excellent antibacterial effect and suppress glucosyltransferase activity. CONSTITUTION: A composition for preventing or treating dental caries contains 0.01-50 wt% of Cannabis sativa extract as an active ingredient. The extract is prepared using an extraction solvent such as water or an organic solvent. The inorganic solvent is alcohol of C1-C4, acetone, or a solution thereof. An oral composition is a toothpaste, oral cleanser, or oral spray. A health functional food for preventing or treating dental caries contains the extract as an active ingredient. The health food is a food or beverage. [Reference numerals] (AA) Cannabis sativa
This is a Phase 1, randomized, blinded, placebo-controlled study in up to approximately 51 non-diabetic obese participants with a BMI ≥ 35 kg/m2. Participants will be blinded, but investigators/site staff and sponsor will be unblinded for Cohort 1. In Cohorts 2 and 3 participants, investigators, and contract research organization personnel are blinded to investigational product and sponsor is unblinded. The participants will participate in the study for up to approximately 27 weeks, including a screening period (including a run-in), treatment period, and safety follow-up.

Participants will be randomized 4:1 to MEDI0382 (n=12) or placebo (n=3) for Cohort 1 and randomized 2:1 to MEDI0382 (n=12) or placebo (n=6) for Cohorts 2 and 3. In Cohort 1 participants randomized to MEDI0382 or placebo will be dosed daily with a weekly titration schedule until the highest clinically tolerated dose (CTD) is established. In Cohort 2 participants randomized to MEDI0382 or placebo will be dosed daily with a 2 week titration schedule up to the highest CTD is established in Cohort 1. In Cohort 3 participants randomized to MEDI0382 or placebo will be dosed daily with a 4 week participants schedule up to the highest CTD established in Cohort 1. Once the highest CTD is identified, participants will continue on the highest CTD for an additional 2 weeks of treatment for Cohort 1 and 3 and additional 4 weeks treatment for Cohort 2. All participants will return 28 days post last dose for a safety follow-up visit.
PURPOSE: A composition containing furanodienone for skin whitening is provided to suppress melanogenesis without cytotoxicity and side effects. CONSTITUTION: A composition for skin whitening contains furanodienone as an active ingredient. The furanodienone is isolated from myrrh using water, ethanol, methanol or butylene glycol. The method for manufacturing the furano dienone from Myrrh includes: a step of obtaining the Myrrh extract it adds in the polar solvent and it heats and extracts Myrrh; a step of obtaining the Myrrh extract it adds in the polar solvent and it heats and extracts Myrrh; a step of obtaining chloroform layer in the extracts aqueous solution; a step of performing chromatography to purify. The furano dienone is included based on the total weight of composition in 0.00001-10 weight%. The composition for skin whitening has formulation of lotion, cream, pack, foundation or the makeup base.
Phenobarbital induces many cytochrome P (oxidative) enzymes. When a single oral 30-mg dose of paroxetine tablets was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine tablets exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment of paroxetine tablets is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect. 450½
BACKGROUND: Breast cancer is the most common form of cancer in women. Adult weight gain and modifiable health behaviors, including smoking, alcohol intake, and lack of physical activity, are well-known risk factors. Most weight gain in women occurs between the ages of 18 and 35 years. Digital interventions have the potential to address logistical challenges that arise in reaching women in this age range. We designed a digital intervention targeting weight gain prevention and other modifiable health behaviors for young women at increased risk of breast cancer. Women aged 18 to 35 years were recruited to this single-arm intervention study over 2 months to test the acceptability and usability of the intervention, which comprised a group welcome event held via videoconferencing, app, and private Facebook group.
OBJECTIVE: This nested qualitative substudy explored women's views and experiences of being part of the digital health intervention to inform future intervention development for a feasibility study.
METHODS: A total of 20 women aged 23 to 35 years who were at increased risk of breast cancer were interviewed via telephone within 1 month after completing the intervention, between February 2023 and March 2023. The women were asked about their experiences of the digital intervention and the extent to which it may have influenced their health behaviors. Data were analyzed thematically and organized using the framework approach.
RESULTS: The interviews lasted for a median of 37 (IQR 30-46) minutes. Overall, the women perceived the digital health intervention comprising education, tracking, and support to be acceptable for weight gain prevention. In total, 4 themes were generated. A "missed opportunity" in breast cancer prevention services encompasses the lack of services that currently exist for young women at increased risk of breast cancer. The pros and cons of being part of a community encompasses the divergent views that the women had regarding engaging with other women at increased risk. The importance of an interactive app focuses on features that the women would want from the app to promote engagement with the intervention. The different wants and needs of different age groups highlights that an intervention such as this one would need to be customizable to suit the needs of women at different life stages.
CONCLUSIONS: There is an unmet need in prevention services for young women aged 18 to 35 years at increased risk of breast cancer. The women perceived the app to be an acceptable intervention for weight gain prevention but emphasized that the intervention would need to be customizable to meet the needs of different age groups within the group of women aged 18 to 35 years. The digital intervention could be a scalable behavior change strategy for UK family history clinics.
PURPOSE:A cosmetic that contains pigments coated with fine amorphous silica films on the particles of the pigments, thus showing high stability to chemical agents, safety to skins and giving refreshing and milk fellings. CONSTITUTION:An inorganic pigment selected from iron oxides, cobalt, manganese, chromium oxide pigments and ultramarine is used as a core and coated with fine amorphous silica deposited and, when necessary, subjected to hydrophobic treatment with an organosilica to improve its dispersibility, and stability. The resultant pigments are added to cosmetics. The amount of the silica coating films is 1-30wt%, preferably 2-20wt%, calculated as SiO2. EFFECT:There is no anxiety of color changes in cosmetics to enable the cosmetic to be used with ease. The rolling effect is developed to improve the dispersibility of the pigment and the quality of the cosmetic.
Esophageal diseases include esophageal obstruction, esophagitis, esophageal stricture, and esophageal diverticulum. Imaging can facilitate the selection of appropriate treatment options and assist in differential diagnosis. Esophageal obstruction in cattle is generally caused by greedy nature of chewing and swallowing of food and foreign structures, including stones, potatoes, trichobezoar, carrots, foodstuffs (i.e., hay), and rice chaff. Esophageal obstruction in cattle can also be caused by artificial procedures, and early detection and treatment are important to avoid severe esophageal injury and its associated risks. Herein, an 11-month-old Japanese black heifer presented with swelling and induration of the neck and snowball crepitation in the subcutaneous area of the left shoulder. Radiography and endoscopy revealed a spring-like foreign body in the esophagus and a cervical esophageal obstruction. Esophageal surgery confirmed that the foreign body was a ruminal mechanical stimulating brush (RB). The case died on day 8 after the initial examination. Pathological necropsy revealed that the RB had entered the esophageal diverticulum and caused esophageal obstruction. This case provides a valuable reminder about the risk of esophageal disease with oral administration procedures.
A medicine for treating kidney stone is provided. The medicine is prepared from following raw materials by weight in parts: 15-25 of polyporus, 15-25 of poria cocos, 15-25 of talcum, 15-25 of rhizoma alismatis, 15-25 of Chinese pink herb, 25-35 of lygodium, 10-20 of chicken's gizzard-skin, 10-20 of seed of cowherb, 10-20 of semen plantaginis, 10-20 of corydalis tuber, 10-20 of bitter orange and 10-20 of donkey-hide gelatin. The raw materials of the medicine are synergistic to improve the internal environment of human body. The medicine directly has effects on sick parts and achieves simultaneous treatment of principal and subordinate symptoms. The medicine dissolves large stones so that the large stones are minified and discharged out of the body. In addition, generation again of the stones is effectively prevented. The medicine is simple in preparation method, convenient to take and low in cost. The effective rate of the medicine can reach over 98%.
The risk of end stage kidney failure among African Americans is 4 times that of Caucasian Americans. This excess risk of kidney failure is largely attributable to mutations in apolipoprotein L1 gene. While 10-15% of African Americans in the United States possess kidney disease-associated ApoL1 mutations, nearly 40% of African Americans on dialysis have these mutations. There are significant gaps in the understanding of the pathophysiology of ApoL1-nephropathy. Only some of the people with ApoL1 mutations develop kidney failure. The pathways that link ApoL1 mutations with end stage kidney failure are not understood. Because kidney biopsy is generally obtained from patients with evidence of kidney disease-whose kidneys have experienced significant damage and sclerosis-access to the relevant kidney cells is very limited. However, recent advancements in biomedical research have made it possible to develop kidney-like cells from inducible pluripotent stem cells (iPSCs) which were derived from blood cells of individuals. This innovative technique will allow us to generate iPSC-derived cells from the blood of individuals who have developed ApoL1-nephropathy for the purpose studying them in research lab so as to decipher the cellular mechanism of their kidney failure.
OBJECTIVE: Our objectives with this study were to describe the frequency of selected cooccurring health conditions and individualized education program (IEP) services and post-high school transition planning for adolescents with autism spectrum disorder and identify disparities by sex, intellectual ability, race or ethnicity, and geographic area.
METHODS: The study sample included 1787 adolescents born in 2004 who were identified as having autism through a health and education record review through age 16 years in 2020. These adolescents were part of a longitudinal population-based surveillance birth cohort from the Autism and Developmental Disabilities Monitoring Network from 2004 to 2020 in 5 US catchment areas.
RESULTS: Attention deficit hyperactivity disorder (47%) and anxiety (39%) were the most common cooccurring health conditions. Anxiety was less commonly identified for those with intellectual disability than those without. It was also less commonly identified among Black adolescents compared with White or Hispanic adolescents. There was wide variation across Autism and Developmental Disabilities Monitoring Network sites in the provision of school-based IEP services. Students with intellectual disability were less likely to receive school-based mental health services and more likely to have a goal for postsecondary independent living skills compared with those without intellectual disability. A total of 37% of students did not participate in standardized testing.
CONCLUSIONS: We identified disparities in the identification of cooccurring conditions and school-based IEP services, practices, and transition planning. Working with pediatric health and education providers, families, and adolescents with autism will be important to identify contributing factors and to focus efforts to reduce disparities in the supports and services adolescents with autism have access to and receive.
BACKGROUND: Tight filum terminale is a rare and challenging condition to diagnose because it presents with nonspecific symptoms and unclear imaging findings. This report documents an atypical case of tight filum terminale.
CASE PRESENTATION: The patient was a previously healthy Asian 18-year-old male presenting with recurrent upper extremity and back pain, initially treated as nonspecific musculoskeletal pain. Notably, the patient's symptoms were inconsistent with the dermatome, showing no correlation with his skin's sensory innervation areas. In contrast to typical tight filum terminale presentations focused on lower extremity and lumbar region disturbances, this patient experienced pain and weakness predominantly in the upper extremities and back, hypothesized to result from traction myelopathy exacerbated by thoracic disc herniation. Investigations including blood and nerve function tests were inconclusive. However, a magnetic resonance imaging scan revealed a combination of tight filum terminale and tiny thoracic disc herniation. A diagnosis of tethered spinal cord syndrome was confirmed following further tests and imaging. The filum terminale was surgically removed, resolving the symptoms at a 7-month follow-up.
CONCLUSIONS: This case underlines the importance of including tight filum terminale as a differential diagnosis in cases of unexplained upper or lower extremity pain. Primary care practitioners, particularly those managing undefined symptoms, should consider tight filum terminale in their diagnostic approach.
Patients will receive 2 encapsulated capsules containing aprepitant 80mg to be ingested with a sip of water 2 hours before surgery and 24 hours after surgery. Surgery will follow our hospital enhanced recovery after surgery (ERAS) standard (general anaesthesia using volatile anaesthetics, intravenous dexamethasone 8mg and ondansetron 4mg for PONV prophylaxis).
PURPOSE: A Nymphaea tetragona extract, a fraction thereof, or a polyphenol-based compound isolated from the fraction is provided to effectively suppress mtGPAT1 activity which causes metabolic diseases, to suppress biosynthesis of neutral fat in a cell, and to increase intake of insulin-dependent glucose in a skeletal muscle cell. CONSTITUTION: A pharmaceutical composition for preventing and treating metabolic diseases contains a Nymphaea tetragona extract as an active ingredient. The extract is prepared using water, C1-C4 alcohols, or a mixture thereof. The pharmaceutical composition contains a fraction which is prepared from the extract using an organic solvent. The organic solvent is selected from the group consisting of hexane, chloroform, and butanol. The pharmaceutical composition also contains a polyphenol-based compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
FIELD: medicine. ^ SUBSTANCE: from affected organs of calves and piglets isolated are epizootic strains of Escherichia coli, producing thermally labial, thermally stable and Shiga-like toxins, as well as of hemolytic strains of Streptococcus bovis and Enterococcus faecalis. Cultures of Escherichia coli, Streptococcus bovis and Enterococcus faecalis are separately grown on nutrient broth at temperature 37C. Cultures of Escherichia coli are grown for 7 days and cultures of Streptococcus bovis and Enterococcus faecalis for 24 hours until concentration of 5-6 billion microbial bodies in 1 ml is achieved. After that grown cultures are separately inactivated with formalin to concentration of 0.3-0.4% during 14 days. After that cultures are mixed in equal volume, packed and sealed. ^ EFFECT: obtained vaccine possesses high immunogenicity and specificity, is harmless. ^ 4 tbl, 1 ex
One object of the present invention is to provide an  H . suis-specific diagnosis method. Another object of the present invention is to provide a simple examination method comprising an  H .  suis -specific diagnosis method that is a non-invasive method. The present inventors newly found that an outer membrane protein (HsvA: named by the present inventor) specifically present exclusively in  H. suis  and an antibody against this protein are present in the body of a subject infected with  H. suis.  Further, the present inventors found a diagnostic method using an amino acid sequence that acts as the antigenic site of HsvA protein. Accordingly, the present invention provides a method whereby  H. suis  can be specifically detected with the use of an  H .  suis -specific antigen comprising an HsvA antigen peptide and an  H. suis- specific DNA derived from hsvA gene.
Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m\^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
The purpose of this pilot research study is to determine if a balance training (BT) class based on the FallProof(TM) approach achieves better balance and mobility outcomes than the current practice. The FallProof's approach focuses on multiple components of balance impairment including multisensory, postural strategy and centre of gravity control training. Current practice is a task-oriented circuit training balance class.

ABI survivors may have muscle weakness, decreased coordination and sensory loss, which contribute to reduced balance, difficulty with functional mobility and activities of daily living. Balance control provides the foundation for a person's ability to stand, walk and function independently. Previous studies indicate that balance training (BT) improves balance, reduces falls, increases walking speed and balance self-efficacy for ABI patients .The Ottawa Panel Evidence-Based Clinical Practice Guidelines for ABI Rehabilitation supported the use of BT based on the research evidence. Interventions such as task-oriented training, multisensory training, trunk control training and perceptual exercises demonstrate positive effect on balance and mobility outcomes. To our knowledge, there are few studies that have examined a multidimensional approach to BT.

A systematic review concluded that exercises performed for 20-60 minutes, 3-4 times a week for 6-12 weeks can improve balance in ABI patients. However, Treacy et al demonstrated that inpatient BT for just 2 weeks can improve balance compared to a control group who received traditional exercise interventions.

At GF Strong Rehabilitation Center (GFS), the usual care provided to the ambulatory ABI patients consists of individualized one to one physiotherapy treatment, as well as a high level BT class. Currently, this BT class is a circuit training class that focuses on task-oriented gait exercises. FallProof balance training is a group- based approach that includes multisensory, postural strategy, centre of gravity control and gait pattern training. It was originally developed for older adults with impaired balance; but there is no research on the effectiveness of this approach for ABI patients. The FallProof approach has been introduced to the low level and intermediate level BT class at GFS, for ABI patients with sever and moderate balance impairments. These classes received positive feedback from patients and therapists. Patients reported improved functional mobility and confidence after attending the class. However, there was no functional outcome measurements collected to compare the effectiveness of the previous class and the new FallProof class. We plan to modify the current circuit training high level balance class with the FallProof approach in the spring of 2017. Before introducing the FallProof class, we would like to collect outcome measures with the current BT class for three months, and then collect collect data with the new class for comparison. We would like to determine if a multidimensional group based BT treatment approach is more effective at improving functional outcomes compared to the current practice.